In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety


	ADR prediction output for the molecular input of erythromycin.

Part of: Ruseva V, Dobrev S, Getova-Kolarova V, Peneva A, Getov I, Dimitrova M, Petkova V (2025) In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety. Pharmacia 72: 1-8. https://doi.org/10.3897/pharmacia.72.e160997